Shonan Beauty Clinic Achieves Highest 'DIAMOND' Certification for 'REJURAN' from PharmaResearch

Shonan Beauty Clinic, managed by SBC Medical Group Holdings (headquartered in Irvine, California, USA; CEO: Yoshiyuki Aikawa, hereinafter "SBC"), has been awarded the highest-tier 'DIAMOND' certification by PharmaResearch (headquartered in Gangwon Province, South Korea; CEO: Jihoon Sohn), the medical manufacturer behind the Korean-origin aesthetic brand 'REJURAN'. This certification program assigns clinic rankings based on REJURAN adoption performance. Shonan Beauty Clinic has been recognized as the only institution in Japan to receive the 'DIAMOND' certification, based on its leading number of REJURAN units purchased and administered domestically.

'VEJURAN' provided by PharmaResearch is a regenerative medicine-derived brand originating from South Korea. It is an injectable treatment designed to enhance the body's natural healing ability, offering a natural anti-aging effect. Widely introduced globally, particularly across Asia, REJURAN has gained significant recognition and acclaim as a leading aesthetic medical brand. Shonan Beauty Clinic was an early adopter of REJURAN and has offered it to a broad customer base as a treatment that promotes skin regeneration. Its high volume of domestic usage has now been recognized, resulting in Shonan becoming the only clinic in Japan to achieve the 'DIAMOND' certification. This level of service delivery is supported by continuous physician education and a robust safety management system.

For more information on REJURAN treatments at Shonan Beauty Clinic, please visit the official website.

SBC Medical Group is committed to strengthening partnerships with innovative medical manufacturers like PharmaResearch, contributing to the healthy development of the aesthetic medicine industry, and striving to deliver optimal, personalized medical care to each individual customer.

About PharmaResearch

PharmaResearch is a leading company in the regenerative medicine field, headquartered in Gangwon Province, South Korea. The company develops and provides regenerative medicine solutions, including patented polynucleotide (PN) formulations. It distributes a wide range of products in the fields of aesthetics, plastic surgery, and dermatology to countries worldwide. Its flagship brand, 'REJURAN', is globally recognized, particularly in Asia, as a treatment that promotes skin repair and regeneration.

Official website: https://pharmaresearch.com

SBC Medical Group Holdings

SBC Medical Group Holdings is a Medical Services Organization (MSO) that provides management support to medical institutions domestically and internationally across a wide range of specialties, including advanced aesthetic medicine, dermatology, plastic surgery, infertility treatment, gynecology, dentistry, hair loss treatment (AGA), and ophthalmology. The group operates multiple clinic brands and is expanding globally, including through medical tourism and into the United States and Asia. In September 2024, it was listed on the U.S. NASDAQ market, and in June 2025, it was selected for inclusion in the U.S. stock index 'Russell 3000'. Moving forward, the group will continue to advance its mission of 'contributing to increasing the happiness of people worldwide through medical innovation' by providing reliable medical services and expanding its network.

English Name: SBC Medical Group Holdings Incorporated

Listed Market: NASDAQ Global Market

Ticker (U.S. Security Code): SBC

Headquarters: 200 Spectrum Center Drive Suite 300, Irvine, CA 92618, USA

CEO: Yoshiyuki Aikawa

Business: Management support services for medical institutions (aesthetic medicine, dermatology, plastic surgery, infertility treatment, gynecology, dentistry, AGA treatment, ophthalmology, and others)

Official Website: https://sbc-holdings.com

Official LinkedIn Page: https://www.linkedin.com/company/sbc-medical-group-holdings-inc

Shonan Beauty Clinic: https://www.s-b-c.net

[Inquiries regarding this announcement]

SBC Medical Group Holdings

Public Relations Department: Murakami Email: [email protected]